- Global Pharma News & Resources

Gastrointestinal Stromal Tumors Drug Pipeline Market Report 2022: Comprehensive Insights About 25+ Companies and 28+ Pipeline Drugs -

DUBLIN--(BUSINESS WIRE)--The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022" clinical trials has been added to's offering.

The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors Emerging Drugs Chapters

This segment of the Gastrointestinal Stromal Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastrointestinal Stromal Tumors Emerging Drugs

Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase III stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST.

Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

DS-6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ("payload") to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.

Designed utilizing Daiichi Sankyo's proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Gastrointestinal Stromal Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastrointestinal Stromal Tumors

There are approx. 25+ key companies which are developing the therapies for Gastrointestinal Stromal Tumors. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

Phases: The report covers around 28+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Gastrointestinal Stromal Tumors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Jiangsu Hengrui Medicine
  • Daiichi Sankyo Company
  • Cogent Biosciences
  • Advenchen Laboratories
  • Chia Tai Tianqing Pharmaceutical Group
  • AB Science
  • Immunicum AB
  • Novartis
  • Bristol-Myers Squibb
  • Hanmi Pharmaceutical Company Limited
  • GlaxoSmithKline
  • Ascentage Pharma
  • Takeda
  • Array BioPharma
  • Plexxikon
  • Arog Pharmaceuticals
  • Xencor, Inc.
  • DNAtrix, Inc.
  • Onyx Pharmaceuticals
  • Exelixis
  • Allarity Therapeutics
  • Theseus Pharmaceuticals
  • IDRx, Inc.
  • Allarity Therapeutics

Key Products

  • Famitinib
  • DS 6157
  • PLX9486
  • Anlotinib
  • Masitinib
  • Intuvax
  • Dovitinib
  • Ipilimumab
  • L-carnitine
  • Pazopanib
  • Nilotinib
  • HQP1351
  • PDR001
  • Ponatinib
  • MEK162
  • Crenolanib besylate
  • XmAb18087
  • TNO155
  • DNX-2440
  • Palbociclib
  • Cabozantinib
  • Pamufetinib
  • THE-630
  • IDRX-42

For more information about this clinical trials report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 11-Oct-2022